MedicalResearch.com Interview with:
Adda Grimberg, MD
Associate Professor of Pediatrics,
Perelman School of Medicine, University of Pennsylvania
Scientific Director, Diagnostic and Research Growth Center
The Children’s Hospital of Philadelphia
Philadelphia, PA 19104
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: This study sought to update the last guidelines for the use of growth hormone (GH) by the Drug and Therapeutics Committee of the Pediatric Endocrine Society (PES), published in 2003, and was the first to be endorsed also by the Ethics Committee of the PES. To facilitate evidence-based decision making, it was the first such GH guidelines to follow the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group. Because idiopathic short stature (ISS) remains a controversial indication, and diagnostic challenges often blur the distinction between ISS, growth hormone deficiency (GHD), and primary insulin-like growth factor-I deficiency (PIGFD), this guidelines statement focused on these three diagnoses and added recombinant IGF-I therapy to the GH guidelines for the first time.